UK small-cap RNS · 1 Apr 2026
The key announcements of UK small & mid caps under £2bn on 1 Apr 2026 – situations they move are marked, with the share price since.
Key = all announcements except routine filings (voting rights, buybacks, holdings, director forms), plus director dealings and holdings that are part of a situation. Not investment advice.
| Date | Company | Mcap ↕ | Type | Announcement | |
|---|---|---|---|---|---|
| 1 Apr | Earnz EARN | £15m | Overhang | Holding(s) in Company | |
| 1 Apr | Genuit Group GEN | £726m | Insider conviction | Director/PDMR Shareholding | |
| 1 Apr | Quantum Helium Limited QHE | £7.2m | Project milestones | Sagebrush Operatorship Approved
Mobilisation for Extended Production Test to Commence After Easter |
|
| 1 Apr | Petra Diamonds Ltd. PDL | £11m | Balance-sheet stress / refinancing | Sales results for Q3 FY 2026 and Sale of 41.82 carat Type IIb blue diamond
Petra Diamonds Limited today provides an update on its Q3 FY 2026 sales results and the sale of the 41.82 carat Type IIb blue diamond, announced on 13 January 2026. |
|
| 1 Apr | Everyman Media Group EMAN | £45m | Insider conviction | Director/PDMR Shareholding | |
| 1 Apr | One Health Group PLC OHGR | £40m | Project milestones | Directorate Change
One Health Group plc (AIM: OHGR), the independent provider of NHS-funded surgical procedures for patients referred by their GP through 'Patient Choice', announces the appointment of Heather Craven as part-time Chief Financial Officer ("CFO"). |
|
| 1 Apr | OptiBiotix Health OPTI | £5.8m | Turnaround plan with targets | Trading Update
Strong period of growth and record start to 2026 |
|
| 1 Apr | Red Rock Resources RRR | £1.6m | Project milestones | Half-year Results
Unaudited Half-Yearly Results for the Six Months Ended |
|
| 1 Apr | CML Microsystems CML | £53m | Upgrade / downgrade cycle | Trading Statement
Second half sees revenue momentum and an improved loss from operations |
|
| 1 Apr | SkinBioTherapeutics SBTX | £16m | New CEO / reset | Statement re. Suspension
1 April 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that trading in the Company's ordinary shares will be suspended with effect from 7.30am today as a consequence of the Company not … |